Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

BACKGROUND: The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II trial by the Food and Drug Administration (FDA). However, r...

Descripción completa

Detalles Bibliográficos
Autores principales: Striefler, Jana Käthe, Brandes, Franziska, Baur, Alexander, Pfitzner, Berit Maria, Kaul, David, Rau, Daniel, Dörr, Anne, Schmiester, Maren, Koulaxouzidis, Georgios, Bullinger, Lars, Märdian, Sven, Flörcken, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988236/
https://www.ncbi.nlm.nih.gov/pubmed/31996176
http://dx.doi.org/10.1186/s12885-020-6551-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988236/
https://www.ncbi.nlm.nih.gov/pubmed/31996176
http://dx.doi.org/10.1186/s12885-020-6551-y

Ejemplares similares